Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.
Source disclosure
This is a source-linked briefing. Read the original report from Pharmaceutical Technology .